Rare diseases
Investigational molecules
Locations
1210-1220 Washington Street Suite 210, 02465-2147, United States
The sponsor concentrates its research efforts on developing therapeutic interventions for neurodegenerative disorders, with particular emphasis on addressing the underlying pathological mechanisms that drive cognitive decline. The research portfolio demonstrates a focused approach to understanding and targeting specific molecular pathways implicated in neurodegeneration.
The investigational work encompasses novel approaches to modifying disease progression through targeting soluble protein aggregates that contribute to synaptic dysfunction and neuronal loss. This research represents efforts to develop disease-modifying treatments that may alter the natural course of progressive cognitive disorders.
Acumen Pharmaceuticals Inc. runs clinical trials in conditions such as Dementia Alzheimer's type, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
